ELAN Q4 2019 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$787M-1.5% YoY

Gross Profit

$326M41.4% margin

Operating Income

$72M9.2% margin

Net Income

-$10M-1.2% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

$126M

Free Cash Flow

$15M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$9.0B

Total Liabilities

$3.4B

Stockholders' Equity

$5.5B

Cash & Equivalents

$334M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$787M	$799M	-1.5%
Gross Profit	$326M	$337M	-3.3%
Operating Income	$72M	$91M	-20.1%
Net Income	-$10M	$16M	-157.9%

Revenue Segments

Food Animal Ruminants And Swine

$299M38%

Food Animal Future Protein And Health

$211M27%

Companion Animal Disease Prevention

$171M22%

Companion Animal Therapeutics

$96M12%